Pelvic Organ Distribution of Mesenchymal Stem Cells Injected Intravenously after Simulated Childbirth Injury in Female Rats

Abstract

The local route of stem cell administration utilized presently in clinical trials for stress incontinence may not take full advantage of the capabilities of these cells. The goal of this study was to evaluate if intravenously injected mesenchymal stem cells (MSCs) home to pelvic organs after simulated childbirth injury in a rat model. Female rats underwent either vaginal distension (VD) or sham VD. All rats received 2 million GFP-labeled MSCs intravenously 1 hour after injury. Four or 10 days later pelvic organs and muscles were imaged for visualization of GFP-positive cells. Significantly more MSCs home to the urethra, vagina, rectum, and levator ani muscle 4 days after VD than after sham VD. MSCs were present 10 days after injection but GFP intensity had decreased. This study provides basic science evidence that intravenous administration of MSCs could provide an effective route for cell-based therapy to facilitate repair after injury and treat stress incontinence.

The Dose-Effect Safety Profile of Skeletal Muscle Precursor Cell Therapy in a Dog Model of Intrinsic Urinary Sphincter Deficiency

“…Cell therapy for urinary incontinence is rapidly moving from the preclinical to the clinical testing stages. As such, the major emphasis of testing has turned to optimization of the cell types and doses and, especially, of its safety [18][19][20]. Most preclinical studies have focused on the functional efficacy, sphincter regeneration, and mechanism of action [18].…”

Homing of chloromethylbenzoyl ammonia-labeled bone marrow mesenchymal stem cells in an immune-mediated bone marrow failure mouse model in vivo

“…Several studies have shown that when tissues are damaged, BMSCs from bone marrow or from the exogenous infusion are generally the first to localize to the inflammation area and damaged tissues with limited efficiency (Park et al, 2011;Cruz et al, 2012). In the model of bone marrow failure, ray irradiation can severely damage the bone marrow hematopoietic cells and the hematopoietic microenvironment.…”

Female urinary incontinence: a systematic overview and non-surgical treatment

“…94 Their potentiality to restore function vias direct effects on the underlying mechanisms leading to incontinence or voiding dysfunction has been evaluated in preclinical animal models and clinical trials, especially for SUI. [95][96][97] Mesenchymal Stem Cells (MSCs), Muscle-Derived Stem Cells (MDSCs), Adipose-Derived Stem Cells (ADSCs) and Urine-Derived Stem Cells (USCs) are the sources of stem cells investigated for therapeutic benefit in urologic applications. 95,[97][98][99] Clinical trials reported improvement in SUI, through great reduction in pad weight, diaryreported leaks and even a complete achievement of continence in women, with no serious adverse events (pain, bruising at biopsy or injection sites).…”